MedTrace Logo

Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

NCT06633003 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-10

No results posted yet for this study

Summary

This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.

Conditions

  • Spinocerebellar Ataxia

Interventions

DIETARY_SUPPLEMENT

Antrodia cinnamomea Products

Placebo-controlled crossover design: * Dietary Supplement: Antrodia Cinnamomea Products * Dietary Supplement: Placebo

DIETARY_SUPPLEMENT

Antrodia cinnamomea Products

A arm : Stage I : • Dietary Supplement: Antrodia Cinnamomea Products Stage II: • Dietary Supplement: Placebo B arm : Stage I : • Dietary Supplement: Placebo Stage II: • Dietary Supplement: Antrodia Cinnamomea Products

Sponsors & Collaborators

  • ALPS Biotech CO. LTD

    lead INDUSTRY

Principal Investigators

  • MingChe Kuo · National Taiwan University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06633003 on ClinicalTrials.gov